blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3264094

EP3264094 - METHODS FOR EVALUATING AN IMMUNE RESPONSE TO A THERAPEUTIC AGENT [Right-click to bookmark this link]
StatusPatent revoked
Status updated on  20.12.2025
Database last updated on 31.03.2026
FormerThe patent has been granted
Status updated on  17.07.2020
FormerGrant of patent is intended
Status updated on  15.03.2020
FormerExamination is in progress
Status updated on  07.09.2018
FormerRequest for examination was made
Status updated on  06.07.2018
FormerThe application has been published
Status updated on  01.12.2017
Most recent event   Tooltip16.01.2026Lapse of the patent in a contracting statepublished on 18.02.2026  [2026/08]
Applicant(s)For all designated states
Biogen MA Inc.
225 Binney Street
Cambridge, MA 02142 / US
[2018/01]
Inventor(s)01 / Subramanyam, Meena
3 Corey Avenue
Stoneham, MA 02180 / US
02 / Amaravadi, Lakshmi
189 South Main Street
Natick, MA 01760 / US
03 / Wakshull, Eric
13 Whittaker Lane
Princeton, MA 01541 / US
04 / Lynn, Frances
44 Albert Road
Windsor, SL4 5BU / GB
05 / Panzara, Michael
73 Bacon Street
Winchester, MA 01890 / US
06 / Barbour, Robin McDaid
250 Normandy Lane
Walnut Creek, CA 94598 / US
07 / Taylor, Julie Elizabeth
1506 7th Avenue
San Francisco, CA 94122 / US
 [2018/01]
Representative(s)Pohlman, Sandra M.
df-mp Patentanwälte Rechtsanwälte PartG mbB
Theatinerstraße 16
80333 München / DE
[N/P]
Former [2018/01]Pohlman, Sandra M.
df-mp Dörries Frank-Molnia & Pohlman
Patentanwälte Rechtsanwälte PartG mbB
Theatinerstrasse 16
80333 München / DE
Application number, filing date17174144.004.04.2006
[2018/01]
Priority number, dateUS20050668404P04.04.2005         Original published format: US 668404 P
[2018/01]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3264094
Date:03.01.2018
Language:EN
[2018/01]
Type: B1 Patent specification 
No.:EP3264094
Date:19.08.2020
Language:EN
[2020/34]
Search report(s)(Supplementary) European search report - dispatched on:EP01.12.2017
ClassificationIPC:G01N33/68
[2018/01]
CPC:
G01N33/686 (EP,US); G01N33/6854 (US); A61P1/00 (EP);
A61P13/12 (EP); A61P17/00 (EP); A61P19/02 (EP);
A61P25/00 (EP); A61P29/00 (EP); A61P35/00 (EP);
A61P35/02 (EP); A61P37/00 (EP); A61P37/02 (EP);
A61P37/06 (EP); C07K16/2839 (US); G01N2333/70546 (EP,US);
G01N2800/065 (EP,US); G01N2800/102 (EP,US); G01N2800/285 (EP,US);
G01N2800/52 (US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2018/32]
Former [2018/01]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  NL,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
Extension statesAL03.07.2018
BA03.07.2018
HR03.07.2018
MK03.07.2018
YU03.07.2018
TitleGerman:VERFAHREN ZUR BEWERTUNG EINER IMMUNREAKTION AUF EIN THERAPEUTISCHES MITTEL[2018/01]
English:METHODS FOR EVALUATING AN IMMUNE RESPONSE TO A THERAPEUTIC AGENT[2018/01]
French:PROCÉDÉS POUR ÉVALUER UNE RÉPONSE IMMUNITAIRE À UN AGENT THÉRAPEUTIQUE[2018/01]
Examination procedure02.06.2017Date on which the examining division has become responsible
03.07.2018Amendment by applicant (claims and/or description)
03.07.2018Examination requested  [2018/32]
07.09.2018Despatch of a communication from the examining division (Time limit: M04)
14.01.2019Reply to a communication from the examining division
17.02.2020Cancellation of oral proceeding that was planned for 04.03.2020
04.03.2020Date of oral proceedings (cancelled)
16.03.2020Communication of intention to grant the patent
10.07.2020Fee for grant paid
10.07.2020Fee for publishing/printing paid
10.07.2020Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP06749243.9  / EP1872136
EP13158951.7  / EP2645106
Divisional application(s)EP20191086.6  / EP3796003
Opposition(s)Opponent(s)01  18.05.2021  26.05.2021  ADMISSIBLE
Polpharma Biologics S.A.
Ul. Trzy Lipy 3
80-172 Gdansk / PL
Opponent's representative
Wichmann, Hendrik
Wuesthoff & Wuesthoff
Patentanwälte und Rechtsanwalt PartG mbB
Schweigerstraße 2
81541 München / DE
 [2024/15]
Former [2021/25]
Opponent(s)01  18.05.2021   
Polpharma Biologics S.A.
Ul. Trzy Lipy 3
80-172 Gdansk / PL
Opponent's representative
Wichmann, Hendrik
Wuesthoff & Wuesthoff
Patentanwälte PartG mbB
Schweigerstraße 2
DE-81541 München / DE
04.06.2021Invitation to proprietor to file observations on the notice of opposition
13.10.2021Reply of patent proprietor to notice(s) of opposition
25.04.2023Date of oral proceedings
22.05.2023Despatch of interlocutory decision in opposition
22.05.2023Despatch of minutes of oral proceedings
19.12.2025Legal effect of revocation of patent [2026/05]
19.12.2025Despatch of communication that the patent will be revoked
Appeal following opposition06.07.2023Appeal received No.  T1253/23
06.07.2023Payment of appeal fee
02.10.2023Statement of grounds filed
16.12.2025Result of appeal procedure: revocation of the patent
19.12.2025Despatch of the decision of the Board of Appeal
26.07.2023Appeal received No.  T1253/23
26.07.2023Payment of appeal fee
29.09.2023Statement of grounds filed
16.12.2025Result of appeal procedure: revocation of the patent
19.12.2025Despatch of the decision of the Board of Appeal
Fees paidRenewal fee
02.06.2017Renewal fee patent year 03
02.06.2017Renewal fee patent year 04
02.06.2017Renewal fee patent year 05
02.06.2017Renewal fee patent year 06
02.06.2017Renewal fee patent year 07
02.06.2017Renewal fee patent year 08
02.06.2017Renewal fee patent year 09
02.06.2017Renewal fee patent year 10
02.06.2017Renewal fee patent year 11
02.06.2017Renewal fee patent year 12
25.04.2018Renewal fee patent year 13
30.04.2019Renewal fee patent year 14
31.03.2020Renewal fee patent year 15
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipFR30.04.2025
[2026/08]
Documents cited:Search[Y] WO03016909  (LUDWIG INST CANCER RES et al.)
 [I]   DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; April 2004 (2004-04-01), SANDS BRUCE E ET AL: "Safety and tolerability of natalizumab in patients concurrently receiving infliximab in a phase 2 study of active Crohn's disease", XP002401100, Database accession no. PREV200600085330
 [I]   GASTROENTEROLOGY, vol. 126, no. 4, Suppl. 2, April 2004 (2004-04-01), DIGESTIVE DISEASE WEEK/105TH ANNUAL MEETING OF THE AMERICAN-GASTROENTEROLOGICAL-ASSOCIATION; NEW ORLEANS, LA, USA; MAY 16 20, 2004, pages A463, ISSN: 0016-5085
 [X]   CALABRESI PETER A ET AL: "Safety and tolerability of natalizumab: Results from the SENTINEL trial", NEUROLOGY, vol. 64, no. 6, Suppl. 1, March 2005 (2005-03-01), & 57TH ANNUAL MEETING OF THE AMERICAN-ACADEMY-OF-NEUROLOGY; MIAMI BEACH, FL, USA; APRIL 09 -19, 2005, pages A277, XP009073089, ISSN: 0028-3878
 [I]   ENNS R ET AL: "Enact-2 safety, tolerability, and immunogenicity results of natalizumab in patients with Crohn's disease", AMERICAN JOURNAL OF GASTROENTEROLOGY, vol. 99, no. 10, Suppl. S, October 2004 (2004-10-01), & 69TH ANNUAL MEETING OF THE AMERICAN-COLLEGE-OF-GASTROENTEROLOGY; ORLANDO, FL, USA; OCTOBER 29 -NOVEMBER 03, 2004, pages S269, XP009073091, ISSN: 0002-9270
 [Y]   BAERT F ET AL: "INFLUENCE OF IMMUNOGENICITY ON THE LONG-TERM EFFICACY OF INFLIXIMAB IN CROHN'S DISEASE", NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, BOSTON, MA, US, vol. 348, no. 7, 13 February 2003 (2003-02-13), pages 601 - 608, XP009037271, ISSN: 1533-4406

DOI:   http://dx.doi.org/10.1056/NEJMoa020888
 [Y]   ROSKOS L K ET AL: "HUMAN ANTIGLOBULIN RESPONSES", MEASURING IMMUNITY, ELSEVIER,, NL, December 2004 (2004-12-01), pages 172 - 186, XP008058931
by applicantUS5840299
 US6602503
 US5888507
 US2003070185
 US5789650
 WO9634096
 EP0239400
 US5693761
 US6407213
 WO9007861
 US5693762
 US5585089
 US5530101
 US5798230
 US2003232333
 US4399216
 US4634665
 US5179017
 US5648260
 US5849992
 US3817837
 US3850752
 US3939350
 US3996345
 US4277437
 US4275149
 US4366241
 US4472509
 US4938948
   SHEREMATA ET AL., NEUROLOGY, vol. 52, 1999, pages 1072 - 1074
   SHEREMATA ET AL., NEUROLOGY, vol. 52, 1999, pages 1072
   SANCHEZ-MADRID ET AL., EUR. J. IMMUNOL., vol. 16, 1986, pages 1343 - 1349
   HEMLER ET AL., J. BIOL. CHEM., vol. 2, 1987, pages 11478 - 11485
   ISSEKUTZ; WYKRETOWICZ, J. IMMUNOL., vol. 147, 1991, pages 109
   PULIDO ET AL., J. BIOL. CHEM., vol. 266, no. 16, 1991, pages 10241 - 10245
   "Molecular Cloning: A Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS
   "Current Protocols in Molecular Biology", JOHN WILEY & SONS, INC.
   "Current Protocols in Molecular Biology", 1989, JOHN WILEY & SONS, pages: 6.3.1 - 6.3.6
   GREEN ET AL., NATURE GENETICS, vol. 7, 1994, pages 13 - 21
   RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 327
   VERHOEYEN ET AL., SCIENCE, vol. 239, 1988, pages 1534 - 1536
   QUEEN ET AL., PROC NATL ACAD SCI USA., vol. 86, no. 24, December 1989 (1989-12-01), pages 10029 - 10033
   TEMPEST ET AL., BIOTECHNOLOGY, vol. 9, 1991, pages 266 - 271
   BOERNER ET AL., J. IMMUNOL., vol. 147, 1991, pages 86 - 95
   PERSSON ET AL., PROC. NAT. ACAD. SCI. USA, vol. 88, 1991, pages 2432 - 2436
   HUANG; STOLLAR, J. IMMUNOL. METHODS, vol. 141, 1991, pages 227 - 236
   VAUGHAN ET AL., NAT BIOTECHNOL., vol. 14, no. 3, March 1996 (1996-03-01), pages 309 - 314
   HOOGENBOOM ET AL., IMMUNOTECHNOLOGY, vol. 4, 1998, pages 1 - 20
   HOOGENBOOM ET AL., IMMUNOL TODAY, vol. 2, 2000, pages 371 - 378
   POWERS ET AL., J IMMUNOL METHODS, vol. 251, 2001, pages 123 - 135
   URLAUB; CHASIN, PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4216 - 4220
   KAUFMAN; SHARP, MOL. BIOL., vol. 159, 1982, pages 601 - 621
   BURTON; WOOF, ADV. IMMUNOL., vol. 51, 1992, pages 1 - 84
   JEFFERIS ET AL., IMMUNOL. REV., vol. 163, 1998, pages 59 - 76
OppositionUS66840405
 EP17174144
 WO2006107962
 WO2007103112
   "FDA grants accelerated approval of TYSABRI, formerly antegren, for the treatment of MS", EUREKALERT, 23 November 2004 (2004-11-23), XP055809841
   MIRE-SLUIS ET AL.: "Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 289, 2004, pages 1 - 16, XP004520874

DOI:   http://dx.doi.org/10.1016/j.jim.2004.06.002
   KUUS-REICHEL ET AL.: "Will immunogenicity limit the Use, Efficacy and the Future Development of therapeutic monoclonal Antibodies?", CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 1994, pages 365 - 372, XP055809845
   ROSKOS ET AL.: "Measuring Immunity, Lotze & Thomson", 2004, ISBN: 0-12-455900-X, article "HUMAN ANTIGLOBULIN RESPONSES", XP008058931
   TUBRIDY ET AL.: "The effect of anti-alpha4 integrin antibody on brain lesion activity in MS", AMERICAN ACADEMY OF NEUROLOGY, 1999, XP008050557
   NOSEWORTHY ET AL.: "Natalizumab", NATURE REVIEWS DRUG DISCOVERY, vol. 4, February 2005 (2005-02-01), pages 101 - 102, XP009123651, DOI: 10.1038/nrd1637

DOI:   http://dx.doi.org/10.1038/nrd1637
   "Natalizumab", NATURE REVIEW, vol. 4, 2005, pages 101 - 102, XP009123651

DOI:   http://dx.doi.org/10.1038/nrd1637
   CALABRESI ET AL., NEUROLOGY, vol. 64, no. 1, March 2005 (2005-03-01)
   CALABRESI ET AL.: "The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL", NEUROLOGY, vol. 69, 2007, pages 1391 - 1403, XP002694856

DOI:   http://dx.doi.org/10.1212/01.wnl.0000277457.17420.b5
   SUBRAMANYAM M: "Case Study: Immunogenicity of Natalizumab", BIOTECHNOLOGY: PHARMACEUTICAL ASPECTS, 2008, pages 173 - 187, XP055476763
   SHEREMATA ET AL.: "A Safety and Pharmacokinetic Study of Intravenous Natalizumab in Patients with MS", NEUROLOGY, vol. 52, 1999, pages 1072 - 1074, XP002997442
   "Antibody product catalogue", MAINE BIOTECHNOLOGY SERVICES INC., 2015, XP055476851
   RISPENS ET AL.: "Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibody", ANAL. BIOCHEM., vol. 411, 2011, pages 271 - 276, XP028171776

DOI:   http://dx.doi.org/10.1016/j.ab.2011.01.001
   ANONYMOUS: "TYSABRI (natalizumab) DESCRIPTION", FDA, 8 March 2005 (2005-03-08), pages 1 - 11, XP093039260
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.